The Society for Eczema Studies (SES) organized a continuing medical education (CME) program titled 'Atopic Dermatitis Update 2026' in Varanasi on Saturday. The session focused on recent advances in the management of atopic dermatitis (AD) and brought together leading dermatology experts from across India.
Prevalence and Impact of Atopic Dermatitis
Experts highlighted that AD, an inflammatory skin disorder, remains a major public health concern, affecting nearly 10% of adults and up to 20% of children globally. In India, prevalence ranges between 0.98% and 9.2%, with a noticeable increase attributed to evolving environmental factors. The condition significantly impacts quality of life, especially in moderate-to-severe cases, causing chronic itching, sleep disruption, and anxiety. It often leads to emotional distress, social isolation, and limits daily activities, while placing considerable emotional and financial burden on families.
Knowledge Gaps and Treatment Challenges
Dr. Sandipan Dhar, President of SES, stated that atopic dermatitis continues to be an under-recognized yet deeply impactful chronic condition in India. Through initiatives like Atopic Dermatitis Update 2026, the goal is to bridge knowledge gaps, share emerging evidence, and empower dermatologists with the latest therapeutic advancements. The discussions underscored persistent treatment gaps despite the availability of conventional therapies such as DMARDs (methotrexate and hydroxychloroquine) and biologics like Dupilumab and Rituximab. Experts noted that challenges remain in achieving long-term disease control, effectively managing severe cases, and addressing symptoms like intense itching.
Advancements in Treatment Options
The CME also highlighted advancements in treatment options, including the role of newer therapies such as JAK inhibitors like Tofacitinib and Upadacitinib, which have been approved by the USFDA for moderate-to-severe AD. These therapies were discussed for their potential to offer faster itch relief, improved skin clearance, and flexible dosing options tailored to individual patient needs.
